Host Jessica Seidelman, MD and guests Kerry LaPlante, Pharm.D., FCCP, FIDSA, FIDP, and Julie Ann Justo, Pharm.D. continue discussing long-acting antibiotics, systemic vs. oral antibiotics, and drug and dosing perspectives in episode 2 of this 3-part conversation. This episode is sponsored by BONESUPPORT™, makers of CERAMENT® G with Gentamicin. CERAMENT G is an FDA-designated breakthrough device offering proven bone remodeling with reliable elution of broad-spectrum Gentamicin. CERAMENT G has a 96% success rate in eradication of infection in a single-stage for patients with fracture related infections and chronic osteomyelitis. To learn more and review CERAMENT G cases, visit their website at BONESUPPORT.com

Listen to Breakpoints: The SIDP Podcast

References:

“Antibiotic Therapy for 6 or 12 Weeks for Prosthetic Joint Infection” PMID 34042388

“NDM-9 resistance to taniborbactam” PMID 36796395 

“Wide dissemination of Gram-negative bacteria producing the taniborbactam-resistant NDM-9 variant: a One Health concern” PMID 37394537

IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections https://www.idsociety.org/practice-guideline/amr-guidance/

“Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety” PMID 30648126

“Corynebacterium striatum Prosthetic Joint Infection Successfully Treated with Long-Term Dalbavancin” PMID 36985124

“Emergence of Dalbavancin, Vancomycin, and Daptomycin Nonsusceptible Staphylococcus aureus in a Patient Treated with Dalbavancin: Case Report and Isolate Characterization” PMID 35510938

“Local antibiotic delivery via intra-articular catheter infusion for the treatment of periprosthetic joint infection: a systematic review” PMID 38691147

“A High-Affinity Native Human Antibody Disrupts Biofilm from Staphylococcus aureus Bacteria and Potentiates Antibiotic Efficacy in a Mouse Implant Infection Model” PMID 26833157

FOLLOW us on X  @jointapproach or Instagram @jointapproachpodcast for more announcements and content, and reach out to us at [email protected]